Drugging DNA repair to target T-ALL cells?

摘要

Despite recent progress in treatment, prognostication for T-cell acute lymphoblastic leukemia (T-ALL) patients, including those with early T-cell precursor ALL (ETP-ALL), is rather poorTherefore, new therapies are needed to extend the complete remission time/cure and/or to treat refractory T-ALL/ETP-ALL patients.